

Special Issue

Diagnostic and Treatment for Three Urological Cancers: Bladder Cancer, Kidney Cancer and Prostate Cancer

Message from the Guest Editor

The therapeutic choices available for urological cancers have witnessed significant advancement in recent years, with the new applications of imaging, targeted therapy, and robotic surgery. We are seeking high impact review or research papers for our upcoming Special Issue focusing on diagnosis and treatments of three urological cancers (prostate, bladder, and kidney cancer). Diagnostic options related to molecular signature/platform, AI and novel urine/blood biomarkers related to therapy or molecular subtypes. Therapeutic options relating to new technology or biomarker implementations and selections, as well as those focusing on specific clinical scenarios, such as localized or metastatic disease, are desirable; those describing or implementing novel techniques are also welcome. Prof. Tarek Bismar

Guest Editor

Prof. Dr. Tarek A. Bismar

Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada

Deadline for manuscript submissions

closed (20 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/81734

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)